While 41% of HIV-negative people from sexual and gender minorities in the UK are taking PrEP, figures drop to below 15% in most of the Balkans and eastern Europe, according to results from the European MSM Internet Survey (EMIS) 2024. Too many people stop taking PrEP when they still need it, and this is often due to access difficulties, Professor Kai Jonas of the University of Maastricht told the 2nd European Workshop on Breaking PrEP Barriers, organised by BCN Checkpoint in Barcelona last week.
Almost all European PrEP users are taking tenofovir disoproxil/emtricitabine pills – the two injectable versions of PrEP are not yet available in the public healthcare system of any country in mainland Europe.
Read the full news story at aidsmap.
Source : aidsmap
Related HIV and Co-Infections News
-
WHO: Integrated drug resistance action framework for HIV, hepatitis B and C and STIs, 2026–2030
-
ECDC evidence brief: Progress towards earlier diagnosis of HIV and viral hepatitis in migrants and mobile populations in the EU/EEA
-
Gilead joins partners for delivery of first shipments of breakthrough twice-yearly lenacapavir for HIV prevention to sub-Saharan Africa
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.